Compound Summary
LE 300
Compound Information
LE 300
Compound Name: | LE 300 |
Compound CID: | 4350931 |
Synonyms: | LE 300 274694-98-3 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benzdindolo2,3-gazecine LE300 CHEMBL441618 More... |
Iupac Name: | 11-methyl-11,21-diazatetracyclo[12.7.0.03,8.015,20]henicosa-1(14),3,5,7,15,17,19-heptaene |
InChI: | InChI=1S/C20H22N2/c1-22-12-10-15-6-2-3-7-16(15)14-20-18(11-13-22)17-8-4-5-9-19(17)21-20/h2-9,21H,10-14H2,1H3 |
InChIKey: | YEWGIGCYIAMFMA-UHFFFAOYSA-N |
Canonical Smiles: | CN1CCC2=CC=CC=C2CC3=C(CC1)C4=CC=CC=C4N3 |
Isomeric Smiles: | CN1CCC2=CC=CC=C2CC3=C(CC1)C4=CC=CC=C4N3 |
Molecular Weight: | 290.4 |
Molecular Formula: | C20H22N2 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
LE 300
Molecular Weight: | 290.4 |
Molecular Formula: | C20H22N2 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 1 |
Rotatable Bond Count: | 0 |
Heavy Atom Count: | 22 |
Complexity: | 369 |
Synonyms
LE 300
| LE 300 | LE 300 |
|---|---|
LE 300 |
274694-98-3 |
7-Methyl-6,7,8,9,14,15-hexahydro-5H-benzdindolo2,3-gazecine |
LE300 |
CHEMBL441618 |
LSM-2007 |
C20H22N2 |
SR-01000075963 |
LE-300 |
Tocris-1674 |
LE 300, solid |
Lopac-L-8401 |
L 8401 |
Lopac0_000699 |
MLS002153328 |
SCHEMBL12610513 |
CHEBI:92030 |
DTXSID20402244 |
HMS2233O19 |
HMS3262K19 |
HMS3268M15 |
HMS3372E16 |
ZINC1486281 |
ZKA69498 |
Tox21_500699 |
BDBM50088341 |
AKOS024456742 |
CCG-204784 |
LP00699 |
SDCCGSBI-0050677.P002 |
NCGC00015614-01 |
NCGC00015614-02 |
NCGC00015614-03 |
NCGC00015614-04 |
NCGC00015614-05 |
NCGC00015614-08 |
NCGC00025255-01 |
NCGC00025255-02 |
NCGC00025255-03 |
NCGC00261384-01 |
SMR001230741 |
B6824 |
EU-0100699 |
J-016773 |
SR-01000075963-1 |
SR-01000075963-3 |
BRD-K01648091-001-01-8 |
BRD-K01648091-001-04-2 |
Q27163823 |
6,7,8,9,14,15-Hexahydro-7-methyl-5H -indolo3,2-f3benzazecine |
6,7,8,9,14,15-Hexahydro-7-methyl-5H-indolo3,2-f3benzazecine |
7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo3,2-f3-benzazecine |
7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo3,2-f3benzazecine |
7-methyl-6,7,8,9,14,15-hexahydro-5H-benzo7,8azecino5,4-bindole(LE 300) |
11-methyl-11,21-diazatetracyclo12.7.0.0^{3,8}.0^{15,20}henicosa-1(14),3(8),4,6,15,17,19-heptaene |
11-methyl-11,21-diazatetracyclo12.7.0.03,8.015,20henicosa-1(14),3,5,7,15,17,19-heptaene |
3-Methyl-1,2,3,4,5,8-hexahydro-(14,15-1,4butanediylidene-(7,6-(iminoethano)-3-benzoazecine))-17-ene |
Experimental Data
LE 300
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | -6.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
LE 300
Statistics Data
LE 300
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -6.000000000000000 | 1 | 1 |
Statistics Data Visualization
LE 300
